

Product Specification Sheet

Product Name: LY2886721

Catalog Number: C5288

Technical information:

Chemical Formula: $C_{18}H_{16}F_2N_4O_2S$

CAS #: 1262036-50-9

Molecular Weight: 390.41

Purity: > 98%


Appearance: White solid

Solubility: Soluble in DMSO up to 20 mM

Chemical Name: N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.256 mL of DMSO for each mg of LY2886721
 - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity: LY2886721 is an orally-available, furothiazine-based inhibitor of b-amyloid protein cleaving enzyme (BACE) for the treatment of Alzheimer's disease. [1] It inhibits recombinant hBACE1 with an IC₅₀ of 20 nM. [2] In cellular assays, LY2886721 inhibits Abeta with an IC₅₀ range of 10-19 nM. Oral administration of LY2886721 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99, and sAPPbeta. [2]

- Reference:**
1. Alzheimer's Disease Research Unit Studies synopsis (April 1, 2012)
 2. Alzheimer Association International Conference, 2012, Oral Sessions (O1-06-03): "Preclinical Characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease"

To reorder: <http://www.cellagentech.com/LY2886721/>

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.